Speaker
Mr
Ján Kozempel
(European Commission, IHCP - JRC, Ispra)
Description
Engineered nanoparticles are of current interest in many applications (e.g. industry, medicine, energy). As they are produced in ever higher quantities, the need to assess their biokinetics and toxicity becomes more and more important. The aim of this study was to prepare stable, radiolabelled bioavailable TiO2 nanoparticles to assess their in vivo biokinetics. The preparation of [48V]TiO2 nanoparticles by direct proton irradiation is described.
Irradiations were performed on the Scanditronix MC-40 cyclotron at JRC Ispra, Italy with a 5 μA proton beam of 23.5 MeV energy. After 16 hours irradiation, a commercial sample of TiO2 (ST-01, Ishihara Corp. Japan) yielded approx. 40 MBq of 48V activity at EOB. Half of the irradiated material was processed two weeks after EOB to size-select and purify the labelled nanoparticles from free 48V by centrifugation and filtration. This yielded 855 kBq of final suspension of fine [48V]TiO2 labeled nanoparticles (Z average = 105 nm) without free 48V. In vivo results in a rat model indicated good 48V label stability with less than 1% of the administered dose eliminated by renal excretion, compared to ionic 48V with approximately 50% renal clearance.
Acknowledgement: This work is funded by the European Commission’s 7th Framework Programme, ”NeuroNano” project (contract NMP4-SL-2008-214547)
Primary author
Mr
Ján Kozempel
(European Commission, IHCP - JRC, Ispra)
Co-authors
Dr
Alexander Wenk
(Institute of Lung Biology and Disease, Helmholtz Centre Munich)
Dr
Federica Simonelli
(European Commission, IHCP - JRC, Ispra)
Ms
Izabela Cydzik
(European Commission, IHCP - JRC, Ispra)
Dr
Kamel Abbas
(European Commission, IHCP - JRC, Ispra)
Prof.
Kenneth Dawson
(Centre for BioNano Interactions, University College Dublin)
Dr
Manuela Semmler-Behnke
(Institute of Lung Biology and Disease, Helmholtz Centre Munich)
Dr
Neil Gibson
(European Commission, IHCP - JRC, Ispra)
Dr
Sonia Ramirez-Garcia
(Centre for BioNano Interactions, University College Dublin)
Dr
Uwe Holzwarth
(European Commission, IHCP - JRC, Ispra)
Dr
Wolfgang Kreyling
(Institute of Lung Biology and Disease, Helmholtz Centre Munich)
